CoChat
Sign Up
Cited by 45

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

RETRACTED: MicroRNA-128 knockout inhibits the development of Alzheimer's disease by targeting PPARγ in mouse models

Liu, Yanqiu, Zhang, Yuzhen, Liu, Ping, Bai, Hongying, Li, Xiaodong, Xiao, Jianhao, Yuan, Qian, Geng, Shuang, Yin, Honglei, Zhang, Hui, Wang, Zhen, Li, Jinfeng, Wang, Shanshan, Wang, Yunliang·2019·European Journal of Pharmacology
DOI 10.1016/j.ejphar.2018.11.004
Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD) is a great threat for the health and life of elderly people. MicroRNA-128 (miR-128) has been reported to be abnormally expressed in the brain of AD patients and associated with the pathogenesis of AD. Our study aimed to have a deep insight into the roles and molecular basis of miR-128 in the development and progression of AD. The cognitive ability and exploratory behaviors were assessed by morris water maze and open-field tests, respectively. The concentrations of amyloid-β (Aβ) 40, Aβ 42, tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 and activity of β-secretase and α-secretase were determined by corresponding ELISA commercial kits. RT-qPCR assay was performed to detect miR-128 level and the mRNA expression of peroxisome proliferator-activated receptor gamma (PPARγ), ionized calcium-binding adaptor molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP). Western blot assay was conducted to determine protein expression of PPARγ, amyloid precursor protein (APP), β-APP cleaving enzyme (BACE1), sAPPα and sAPPβ. The effect of miR-128 and PPARγ on amyloid plaque formation was assessed by immunohistochemistry assay. PPARγ mean optical density was determined by immunofluorescence assay. The interaction between miR-128 and PPARγ were validated by bioinformatics analysis and luciferase reporter assay. We found AD mice showed AD-like performance and an increased cerebral cortex Aβ production. MiR-128 expression was upregulated and PPARγ expre…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ejphar.2018.11.004This paper is marked retracted.

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 41

  1. Basavaraju, 2016, Alzheimer's disease: presence and role of microRNAs, Biomol. Concepts, 7, 241, 10.1515/bmc-2016-0014 · DOI
  2. Brookmeyer, 2017, Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States, Alzheimers Dement., 14, 121, 10.1016/j.jalz.2017.10.009 · DOI · Paper page
  3. Chen, 2012, Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders, Mol. Neurobiol., 46, 114, 10.1007/s12035-012-8259-8 · DOI
  4. Cheng, 2014, beta-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARgamma pathway, Pharmacology, 94, 1, 10.1159/000362689 · DOI
  5. Di, 2016, MicroRNAs as therapeutic targets for Alzheimer's disease, J. Alzheimers Dis., 53, 367, 10.3233/JAD-160203 · DOI
  6. Dickson, 2013, Alternative polyadenylation and miR-34 family members regulate tau expression, J. Neurochem., 127, 739, 10.1111/jnc.12437 · DOI
  7. Escribano, 2010, Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology, Neuropsychopharmacology, 35, 1593, 10.1038/npp.2010.32 · DOI · Paper page
  8. Femminella, 2016, The emerging role of microRNAs in Alzheimer's disease, Front. Physiol., 6, 40
  9. Heron, 2016, Deaths: leading causes for 2014, Natl. Vital. Stat. Rep., 65, 1
  10. Janani, 2015, PPAR gamma gene–a review, Diabetes Metab. Syndr., 9, 46, 10.1016/j.dsx.2014.09.015 · DOI · Paper page
  11. Jian, 2017, miR-34a knockout attenuates cognitive deficits in APP/PS1 mice through inhibition of the amyloidogenic processing of APP, Life Sci., 182, 104, 10.1016/j.lfs.2017.05.023 · DOI
  12. Kim, 2015, The multifaceted factor peroxisome proliferator-activated receptor gamma (PPARgamma) in metabolism, immunity, and cancer, Arch. Pharm. Res., 38, 302, 10.1007/s12272-015-0559-x · DOI
  13. Kumar, 2015, A review on Alzheimer's disease pathophysiology and its management: an update, Pharmacol. Rep., 67, 195, 10.1016/j.pharep.2014.09.004 · DOI · Paper page
  14. Landreth, 2008, PPARγ agonists as therapeutics for the treatment of Alzheimer's disease, Neurotherapeutics, 5, 481, 10.1016/j.nurt.2008.05.003 · DOI
  15. Lane, 2018, Alzheimer's disease, Eur. J. Neurol., 25, 59, 10.1111/ene.13439 · DOI · Paper page
  16. Lawson, 2012, p38-alpha MAPK depletion and repression of signal transduction to translation machinery by miR-124 and -128 in neurons, Mol. Cell. Biol., 33, 127, 10.1128/MCB.00695-12 · DOI
  17. Li, 2014, Microglia in Alzheimer's disease, Biomed. Res. Int., 2014, 437483
  18. Lukiw, 2007, Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus, Neuroreport, 18, 297, 10.1097/WNR.0b013e3280148e8b · DOI · Paper page
  19. Medeiros, 2013, Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony, Exp. Neurol., 239, 133, 10.1016/j.expneurol.2012.10.007 · DOI
  20. Mufson, 2016, Molecular and cellular pathophysiology of preclinical Alzheimer's disease, Behav. Brain Res., 311, 54, 10.1016/j.bbr.2016.05.030 · DOI
  21. Nicolakakis, 2010, The nuclear receptor PPARγ as a therapeutic target for cerebrovascular and brain dysfunction in alzheimer's disease, Front. Aging Neurosci., 2
  22. O’Reilly, 2012, Rosiglitazone improves spatial memory and decreases insoluble Aβ in APP/PS1 mice, J. Neuroimmune Pharmacol., 7, 140, 10.1007/s11481-011-9282-7 · DOI
  23. Papagiannakopoulos, 2012, Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases, Oncogene, 31, 1884, 10.1038/onc.2011.380 · DOI · Paper page
  24. Raskin, 2015, Neurobiology of alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions, Curr. Alzheimer Res., 12, 712, 10.2174/1567205012666150701103107 · DOI
  25. Salta, 2017, microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease, FASEB J., 31, 424, 10.1096/fj.201601308 · DOI · Paper page
  26. Sarkar, 2016, Expression of microRNA-34a in Alzheimer's disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity, Brain Res., 1646, 139, 10.1016/j.brainres.2016.05.026 · DOI · Paper page
  27. Shadfar, 2015, Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents, Arch. Pharm. Res., 38, 2106, 10.1007/s12272-015-0648-x · DOI
  28. Tiribuzi, 2014, miR128 up-regulation correlates with impaired amyloid β(1-42) degradation in monocytes from patients with sporadic Alzheimer's disease, Neurobiol. Aging, 35, 345, 10.1016/j.neurobiolaging.2013.08.003 · DOI · Paper page
  29. Ullah, 2014, MicroRNAs with a role in gene regulation and in human diseases, Mol. Biol. Rep., 41, 225, 10.1007/s11033-013-2855-1 · DOI
  30. Vardy, 2005, Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease, Trends Mol. Med., 11, 464, 10.1016/j.molmed.2005.08.004 · DOI
  31. Venkataraman, 2010, MicroRNA 128a Increases Intracellular ROS level by targeting bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence, PLoS One, 5, e10748, 10.1371/journal.pone.0010748 · DOI · Paper page
  32. Vishnoi, 2017, MiRNA biogenesis and regulation of diseases: an overview, Methods Mol. Biol., 1509, 1, 10.1007/978-1-4939-6524-3_1 · DOI
  33. Wang, 2017, Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer's disease, Iran. J. Basic Med. Sci., 20, 474
  34. Wang, 2011, Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter, Acta Neuropathol., 121, 193, 10.1007/s00401-010-0756-0 · DOI · Paper page
  35. Wang, 2015, Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease, Ann. Transl. Med., 3, 136
  36. Wang, 2016, Astragaloside IV, a natural PPARγ agonist, reduces Aβ production in Alzheimer's disease Through inhibition of BACE1, Mol. Neurobiol., 54, 2939, 10.1007/s12035-016-9874-6 · DOI
  37. Xu, 2018, miR-34a deficiency in APP/PS1 mice promotes cognitive function by increasing synaptic plasticity via AMPA and NMDA receptors, Neurosci. Lett., 670, 94, 10.1016/j.neulet.2018.01.045 · DOI
  38. Yan, 2014, Targeting the β secretase BACE1 for Alzheimer's disease therapy, Lancet Neurol., 13, 319, 10.1016/S1474-4422(13)70276-X · DOI
  39. Zeng, 2016, MicroRNA-128 inhibition attenuates myocardial ischemia/reperfusion injury-induced cardiomyocyte apoptosis by the targeted activation of peroxisome proliferator-activated receptor gamma, Mol. Med. Rep., 14, 129, 10.3892/mmr.2016.5208 · DOI
  40. Zhang, 2016, Anxiety-like behavior and dysregulation of miR-34a in triple transgenic mice of Alzheimer's disease, Eur. Rev. Med. Pharmacol. Sci., 20, 2853
  41. Zhao, 2015, MicroRNA-based biomarkers and the diagnosis of Alzheimer's disease, Front. Neurol., 6, 162, 10.3389/fneur.2015.00162 · DOI

Cited by

Sorted by citations

See all 45

Metadata

Authors
Liu, Y., Zhang, Y., Liu, P., Bai, H., Li, X., Xiao, J., Yuan, Q., Geng, S., Yin, H., Zhang, H., Wang, Z., Li, J., Wang, S., & Wang, Y.
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
2019-01
Volume
843
Pages
134-144
ISSN
0014-2999
DOI
10.1016/j.ejphar.2018.11.004
Cited by
45
References
9
Language
en
Status
Retracted
Update notices
Licence
Funders
Health and Family Planning Commission of Hunan Province

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review